Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Prevention of CI-AKI in CVD Patients
NCT04666389Completed
- Sponsor
- Sechenov First Moscow State Medical University
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Atorva in contrast-induced acute kidney injury (CI-AKI) (3 arms), sponsored by Sechenov First Moscow State Medical University. Primary endpoint: Contrast-induced acute kidney injury. Started Oct 2020; status: completed.
02
Drugs
Atorva
03
Conditions
contrast-induced acute kidney injury (CI-AKI)
Beyond the preview
Go deeper on NCT04666389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666389.